Evenity

Draft 

  

 

1 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX I 
 

SUMMARY OF PRODUCT CHARACTERISTICS 
 

 

 

 

 

 



 

Draft 

 
 

2 

This medicinal product is subject to additional monitoring. This will allow quick identification of 

new safety information. Healthcare professionals are asked to report any suspected adverse reactions. 

See section 4.8 for how to report adverse reactions. 

 

 

1. NAME OF THE MEDICINAL PRODUCT 
 

EVENITY 105 mg solution for injection in pre-filled pen 

EVENITY 105 mg solution for injection in pre-filled syringe  

 

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 

EVENITY 105 mg solution for injection in pre-filled pen 

 

Each pre-filled pen contains 105 mg of romosozumab in 1.17 ml of solution (90 mg/ml).  

 

EVENITY 105 mg solution for injection in pre-filled syringe  

 

Each pre-filled syringe contains 105 mg of romosozumab in 1.17 ml of solution (90 mg/ml).  

 

Romosozumab is a humanized IgG2 monoclonal antibody produced using recombinant DNA 

technology in Chinese hamster ovary (CHO) cells. 
 

For the full list of excipients, see section 6.1. 

 

 

3. PHARMACEUTICAL FORM 
 

Solution for injection (injection)  

 

Clear to opalescent, colorless to light yellow solution. 

 

 

4. CLINICAL PARTICULARS 
 

4.1 Therapeutic indications 
 

EVENITY is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of 

fracture (see section 5.1).  

 

4.2 Posology and method of administration 

 

Treatment should be initiated and supervised by specialist physicians experienced in the management 

of osteoporosis. 

 

Posology 

 

The recommended dose is 210 mg romosozumab (administered as two subcutaneous injections of 

105 mg each) once monthly for 12 months. 

 

Patients should be adequately supplemented with calcium and vitamin D before and during treatment 

(see sections 4.3 and 4.4).  

 

Patients treated with EVENITY should be given the package leaflet and the patient alert card. 

 



 

Draft 

 
 

3 

Following completion of romosozumab therapy, transition to antiresorptive therapy is recommended 

in order to extend the benefit achieved with romosozumab beyond 12 months. 

 

Missed doses 

If the romosozumab dose is missed, administer as soon as it can be feasible. Thereafter, the next 

romosozumab dose should not be given earlier than one month after the last dose. 

 

Special populations 

 

Elderly  

No dose adjustment is necessary in elderly patients (see also section 5.2). 

 

Renal impairment 

No dose adjustment is required in patients with renal impairment (see section 5.2). Serum calcium 

should be monitored in patients with severe renal impairment or receiving dialysis (see section 4.4). 

 

 

Hepatic impairment  

No clinical trials have been conducted to evaluate the effect of hepatic impairment (see section 5.2). 

 

Paediatric population  

The safety and efficacy of romosozumab in paediatric patients (age <18 years) have not yet been 

established. No data are available.   

 

Method of administration  

 

Subcutaneous use  

To administer the 210 mg dose, 2 subcutaneous injections of romosozumab should be given into the 

abdomen, thigh, or upper arm. The second injection should be given immediately after the first one but 

at a different injection site. 

 

Administration should be performed by an individual who has been trained in injection techniques.  

 

For instructions on handling and disposal see section 6.6. 

 

4.3 Contraindications 
 

- Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1 
(see section 4.4) 

- Hypocalcaemia (see section 4.4) 
- History of myocardial infarction or stroke (see section 4.4) 
 

 

4.4 Special warnings and precautions for use 

 

Myocardial infarction and stroke 

In randomised controlled studies, an increase in serious cardiovascular events (myocardial infarction 

and stroke) has been observed in romosozumab treated patients compared to controls (see section 4.8).  

 

Romosozumab is contraindicated in patients with previous myocardial infarction or stroke (see section 

4.3). 

 

When determining whether to use romosozumab for an individual patient, consideration should be 

given to her fracture risk over the next year and her cardiovascular risk based on risk factors (e.g. 

established cardiovascular disease, hypertension, hyperlipidaemia, diabetes mellitus, smoking, severe 

renal impairment, age). romosozumab should only be used if the prescriber and patient agree that the 



 

Draft 

 
 

4 

benefit outweighs the risk. If a patient experiences a myocardial infarction or stroke during therapy, 

treatment with romosozumab should be discontinued. 

 

Hypocalcaemia 

Transient hypocalcaemia has been observed in patients receiving romosozumab.  

Hypocalcaemia should be corrected prior to initiating therapy with romosozumab and patients should 

be monitored for signs and symptoms of hypocalcaemia. If any patient presents with suspected 

symptoms of hypocalcaemia during treatment (see section 4.8), calcium levels should be measured. 

Patients should be adequately supplemented with calcium and vitamin D (see sections 4.3 and 4.8).  

 

Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 

29 ml/min/1.73 m2) or receiving dialysis are at greater risk of developing hypocalcaemia and the 

safety data for these patients is limited. Calcium levels should be monitored in these patients. 

 

Hypersensitivity 

Clinically significant hypersensitivity reactions, including angioedema, erythema multiforme, and 

urticaria occurred in the romosozumab group in clinical trials. If an anaphylactic or other clinically 

significant allergic reaction occurs, appropriate therapy should be initiated and use of romosozumab 

should be discontinued (see sections 4.3 and 4.8). 

 

Osteonecrosis of the jaw 

Osteonecrosis of the jaw (ONJ), has been reported rarely in patients receiving romosozumab. The 

following risk factors should be considered when evaluating a patient’s risk of developing ONJ: 

-  potency of the medicinal product that inhibits bone resorption (the risk increases with the 

antiresorptive potency of the compound), and cumulative dose of bone resorption therapy.  

-  cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.  

-  concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to 

head and neck.  

-  poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease, 

invasive dental procedures e.g. tooth extractions.  

 

All patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, 

and immediately report any oral symptoms such as dental mobility, pain or swelling or non-healing of 

sores or discharge during treatment with romosozumab. 

 

Patients who are suspected of having or who develop ONJ while on romosozumab should receive care 

by a dentist or an oral surgeon with expertise in ONJ. Discontinuation of romosozumab therapy should 

be considered until the condition resolves and contributing risk factors are mitigated where possible.   

  

Atypical femoral fractures  

Atypical low-energy or low trauma fracture of the femoral shaft, which can occur spontaneously, has 

been reported rarely in patients receiving romosozumab. Any patient who presents with new or 

unusual thigh, hip, or groin pain should be suspected of having an atypical fracture and should be 

evaluated to rule out an incomplete femur fracture. Patient presenting with an atypical femur fracture 

should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of 

romosozumab therapy should be considered, based on an individual benefit-risk assessment. 

 

Sodium content 

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say  essentially 

sodium-free. 
 

4.5 Interaction with other medicinal products and other forms of interaction 
 

No drug interaction studies have been performed with romosozumab. No pharmacokinetic drug 

interactions are expected with romosozumab. 

 



 

Draft 

 
 

5 

4.6 Fertility, pregnancy and lactation 

 

Pregnancy 

 

Romosozumab is not indicated for use in women of child-bearing potential or in pregnant women. 

There are no data from the use of romosozumab in pregnant women. Skeletal malformations 

(including syndactyly and polydactyly) were observed at a low incidence in a single study with 

romosozumab in rats (see section 5.3). A risk for malformations of developing digits in the human 

foetus is low following romosozumab exposure due to the timing of digit formation in the first 

trimester in humans, a period when placental transfer of immunoglobulins is limited.  

 

Breast-feeding 

 

Romosozumab is not indicated for use in breast-feeding women. 

 

No data are available on excretion of romosozumab in human milk. Human IgGs are known to be 

excreted in breast milk during the first few days after birth, which is decreasing to low concentrations 

soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short 

period.  

 

Fertility 

 

No data are available on the effect of romosozumab on human fertility. Animal studies in female and 

male rats did not show any effects on fertility endpoints (see section 5.3). 

 

4.7 Effects on ability to drive and use machines 
 

Romosozumab has no or negligible influence on the ability to drive and use machines. 

 

4.8 Undesirable effects 

 

Summary of the safety profile 

 

The most common adverse reactions were nasopharyngitis (13.6%) and arthralgia (12.4%). 

Hypersensitivity-related reactions occurred in 6.7% of patients treated with romosozumab. 

Hypocalcaemia was reported uncommonly (0.4% of patients treated with romosozumab). In 

randomised controlled studies, an increase in serious cardiovascular events (myocardial infarction and 

stroke) has been observed in romosozumab treated patients compared to controls (see section 4.4 and 

information below). 

 

Tabulated list of adverse reactions 

 

The following convention has been used for the classification of the adverse reactions: 

very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), 

rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000). Within each frequency grouping and system 

organ class, adverse reactions are presented in order of decreasing seriousness. 

 



 

Draft 

 
 

6 

MedDRA System Organ Class Adverse reaction 
Frequency 

category 

Infections and infestations 
Nasopharyngitis Very common 

Sinusitis Common 

Immune system disorders 

Hypersensitivitya 

Rash 

Dermatitis 

Urticaria  

Angioedema 

Erythema multiforme 

Common 

Common 

Common 

Uncommon  

Rare 

Rare 

Metabolism and nutrition disorders Hypocalcaemiab Uncommon 

Nervous system disorders 
Headache Common 

Strokec Uncommon 

Eye disorders Cataract Uncommon 

Cardiac disorders Myocardial infarctionc Uncommon 

Musculoskeletal and connective tissue 

disorders 

Arthralgia Very common 

Neck pain Common 

Muscle spasms Common 

General disorders and administration site 

conditions 
Injection site reactionsd Common 

a. See sections 4.3 and 4.4. 
b. Defined as albumin adjusted serum calcium that was below the lower limit of normal. See sections 4.3 and 4.4. 
c. See section “Myocardial infarction and stroke” below. 
d. Most frequent injection site reactions were pain and erythema. 
 

Description of selected adverse reactions 

Immunogenicity 

 

In postmenopausal women dosed with monthly romosozumab, the incidence of anti-romosozumab 

antibodies was 18.6% (1162 of 6244) for binding antibodies and 0.9% (58 of 6244) for neutralizing 

antibodies. The earliest onset of anti-romosozumab antibodies was 3 months after first dosing. The 

majority of antibody responses were transient. 

The presence of anti-romosozumab binding antibodies decreased romosozumab exposure by up to 

25%. No impact on the efficacy of romosozumab was observed in the presence of antiromosozumab 

antibodies. Limited safety data show that the incidence of injection site reactions was numerically 

higher in female patients with neutralizing antibodies. 

 

Myocardial infarction, stroke and mortality 

 

In the active-controlled trial of romosozumab for the treatment of severe osteoporosis in 

postmenopausal women during the 12-month double-blind romosozumab treatment phase, 16 women 

(0.8%) had myocardial infarction in the romosozumab arm versus 5 women (0.2%) in the alendronate 

arm and 13 women (0.6%) had stroke in the romosozumab arm versus 7 women (0.3%) in the 

alendronate arm. These events occurred in patients with and without a history of myocardial infarction 

or stroke. Cardiovascular death occurred in 17 women (0.8%) in the romosozumab group and 12 

(0.6%) women in the alendronate group. The number of women with major adverse cardiac events 

(MACE = positively adjudicated cardiovascular death, myocardial infarction or stroke) was 41 (2.0%) 

in the romosozumab group and 22 (1.1%) in the alendronate group, yielding a hazard ratio of 1.87 

(95% confidence interval [1.11, 3.14]) for romosozumab compared to alendronate. All-cause death 

occurred in 30 women (1.5%) in the romosozumab group and 22 (1.1%) women in the alendronate 

group. 

In the placebo-controlled trial of romosozumab for the treatment of osteoporosis in postmenopausal 

women (including women with severe and less severe osteoporosis) during the 12-month double-blind 

romosozumab treatment phase, there was no difference in positively adjudicated MACE; 30 (0.8%) 



 

Draft 

 
 

7 

occurred in the romosozumab group and 29 (0.8%) in the placebo group. All-cause death occurred in 

29 women (0.8%) in the romosozumab group and 24 (0.7%) women in the placebo group. 

 

Reporting of suspected adverse reactions 

 

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 

allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 

professionals are asked to report any suspected adverse reactions via the national reporting system 

listed in Appendix V. 

 

4.9 Overdose 

 

There is no experience with overdose in clinical trials. There is no known antidote to romosozumab or 

specific treatment for overdose. In case of overdose, it is recommended that patients are monitored 

closely and given appropriate treatment. 

 

 

5. PHARMACOLOGICAL PROPERTIES 
 

5.1  Pharmacodynamic properties  
 

Pharmacotherapeutic group: Medicinal products for treatment of bone diseases, medicinal products 

affecting bone structure and mineralization, ATC code: M05BX06. 

 

Mechanism of action 

 

Romosozumab is a humanized monoclonal antibody (IgG2) that binds and inhibits sclerostin, thereby 

increasing bone formation due to the activation of bone lining cells, increasing bone matrix production 

by osteoblasts, and recruitment of osteoprogenitor cells. Additionally, romosozumab results in changes 

to expression of osteoclast mediators, thereby decreasing bone resorption. Together, this dual effect of 

increasing bone formation and decreasing bone resorption results in rapid increases in trabecular and 

cortical bone mass, improvements in bone structure, and strength. 

  

Pharmacodynamic effects 

 

In postmenopausal women with osteoporosis, romosozumab increased the bone formation marker 

procollagen Type 1 N terminal propeptide (P1NP) early in treatment, with a peak increase of 

approximately 145% relative to placebo 2 weeks after initiating treatment, followed by a return to 

placebo levels at month 9 and a decline to approximately 15% below placebo at month 12. 

Romosozumab decreased the bone resorption marker type-1 collagen C-telopeptide (CTX) with a 

maximal reduction of approximately 55% relative to placebo 2 weeks after initiating treatment. CTX 

levels remained below placebo and were approximately 25% below placebo at month 12.  

 

After discontinuation of romosozumab therapy in postmenopausal women with osteoporosis, P1NP 

levels returned to baseline within 12 months; CTX increased above baseline levels within 3 months 

and returned toward baseline levels by month 12, reflecting reversibility of effect. Upon retreatment 

with romosozumab (in a limited number of patients) after 12 months placebo treatment, the levels of 

increase in P1NP and decrease in CTX by romosozumab were similar to that observed during the 

initial treatment. 

 

Clinical trial efficacy 

 

Treatment of osteoporosis in postmenopausal women 

 

Efficacy and safety of romosozumab was assessed in two pivotal studies, an alendronate-controlled 

(ARCH) and a placebo-controlled study (FRAME). 

 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

Draft 

 
 

8 

Study 20110142 (ARCH) 

 

The efficacy and safety of romosozumab in the treatment of osteoporosis in postmenopausal women 

was evaluated in a multicenter, multinational, randomized, double-blind, alendronate-controlled, 

superiority study of 4,093 postmenopausal women aged 55 to 90 years (mean age of 74.3 years) with 

previous fragility fractures.  

 

Enrolled women had either a BMD (Bone Mineral Density) T-score at the total hip or femoral neck of 

≤ −2.50, and either at least 1 moderate or severe vertebral fracture; or at least 2 mild vertebral 

fractures; or a BMD T-score at the total hip or femoral neck of ≤ -2.00, and either at least 2 moderate 

or severe vertebral fractures; or a fracture of the proximal femur that occurred within 3 to 24 months 

prior to randomization.  

 

The mean baseline lumbar spine, total hip, and femoral neck BMD T-scores were -2.96, -2.80, 

and -2.90, respectively, 96.1% of women had a vertebral fracture at baseline, and 99.0% of women 

had a previous osteoporotic fracture. Women were randomized (1:1) to receive either monthly 

subcutaneous injections of romosozumab or oral weekly alendronate in a blinded fashion for 

12 months. After the 12-month double blind study period, women in both arms transitioned to 

alendronate while remaining blinded to their initial treatment. The primary analysis was performed 

when all women had completed the month 24 study visit and clinical fracture events were confirmed 

for at least 330 women and occurred after a median follow-up time of approximately 33 months on 

study. Women received calcium and vitamin D supplementation daily. 

 

The primary efficacy endpoints were the incidence of new vertebral fracture through month 24 and the 

incidence of clinical fracture (nonvertebral fracture and clinical vertebral fracture) at primary analysis.  

 

Effect on new vertebral, clinical, nonvertebral, hip and major osteoporotic fractures  

As shown in Table 1, romosozumab reduced the incidence of new vertebral fracture through month 24 

(adjusted p-value < 0.001) and the incidence of clinical fracture at primary analysis (adjusted p-value 

< 0.001) as well as the incidence of non vertebral fractures at primary analysis (adjusted p-value = 

0.040) versus treatment with alendronate alone. Table 1 also shows nonvertebral, hip and major 

osteoporotic fracture risk reduction through primary analysis, month 12 and month 24. 

 



 

Draft 

 
 

9 

Table 1.  The Effect of romosozumab on the Iincidence and risk of new Vvertebral, clinical, 

nonvertebral, hip and major osteoporotic fractures in post-menopausal women with 

osteoporosis 

 

Proportion of women with 

fracture  
Absolute risk 

reduction 

(%) 

(95% CI) 

Relative risk 

reduction (%) 

(95% CI) 

Alendronate/ 

Alendronate 

(%) 

Romosozumab/ 

Alendronate 

(%) 

New vertebral 

Through month 12 85/1703 (5.0) 55/1696 (3.2) 1.84 (0.51, 3.17) 36 (11, 54) 

Through month 24a 147/1834 (8.0) 74/1825 (4.1) 4.03 (2.50, 5.57) 50 (34, 62) 

Clinicalb 

Through month 12 110/2047 (5.4) 79/2046 (3.9) 1.8 (0.5, 3.1) 28 (4, 46) 

Primary analysis 

(median follow-up 

approx. 33 months) 

266/2047 (13.0) 198/2046 (9.7) NAc 27 (12, 39) 

Nonvertebral 

Through Month 12 95/2047 (4.6) 70/2046 (3.4) 1.4 (0.1, 2.6) 26 (-1, 46) 

Primary analysis 

(median follow-up 

approx. 33 months) 

217/2047 (10.6) 178/2046 (8.7) NAc 19 (1, 34) 

Hip 

Through Month 12 22/2047 (1.1) 14/2046 (0.7) 0.3 (-0.3, 0.9) 36 (-26, 67) 

Primary analysis 

(median follow-up 

approx. 33 months) 

66/2047 (3.2) 41/2046 (2.0) NAc 38 (8, 58) 

Major osteoporoticd 

Through Month 12 85/2047 (4.2) 61/2046 (3.0) 1.4 (0.3, 2.5) 28 (-1, 48) 

Primary analysis 

(median follow-up 

approx. 33 months) 

209/2047 (10.2) 146/2046 (7.1) NAc 32 (16, 45) 

a.  Absolute risk reduction and relative risk reduction based on Mantel-Haenszel method adjusted for age strata, baseline 
total hip BMD T-score (≤ -2.5, > -2.5), and presence of severe vertebral fracture at baseline. Treatment comparisons 

are based on adjusted logistic regression model.  
b. Clinical fractures include all symptomatic fractures including nonvertebral and painful vertebral fractures. Treatment 

comparisons are based on Cox proportional hazards model. 
c. NA: not available as subjects have various exposure at primary analysis. 
d.               Major osteoporotic fractures include hip, forearm, humerus, and clinical vertebral. 

 

 Effect on Bone Mineral Density (BMD)  

In postmenopausal women with osteoporosis, romosozumab for 12 months followed by alendronate 

for 12 months increased BMD compared with alendronate alone at month 12 and 24 (p-value < 0.001) 

(see Table 2).  

 

Following 12 months of treatment, romosozumab increased BMD at the lumbar spine from baseline in 

98% of postmenopausal women.   

 



 

Draft 

 
 

10 

Table 2. Mean percent change in BMD from baseline through month 12 and month 24 in post-

menopausal women with osteoporosis 

 

Alendronate/Alendronate 

Mean (95% CI) 

N = 2047a 

Romosozumab/Alendronate 

Mean (95% CI) 

N = 2046a 

Treatment difference 

from alendronate-to-

alendronate 

At Month 12 

Lumbar spine 5.0 (4.8, 5.2) 12.4 (12.1, 12.7) 7.4b (7.0, 7.8) 

Total hip  2.9 (2.7, 3.1) 5.8 (5.6, 6.1) 2.9b (2.7, 3.2) 

Femoral neck 2.0 (1.8, 2.2) 4.9 (4.6, 5.1) 2.8b (2.5, 3.2) 

At Month 24 

Lumbar spine 7.2 (6.9, 7.5) 14.0 (13.6, 14.4) 6.8b (6.4, 7.3) 

Total hip  3.5 (3.3, 3.7) 6.7 (6.4, 6.9) 3.2b (2.9, 3.6) 

Femoral neck 2.5 (2.3, 2.8) 5.7 (5.4, 6.0) 3.2b (2.8, 3.5) 

Means and confidence intervals are based on patients with available data. Based on ANCOVA model; missing values of 

baseline BMD and BMD percent change from baseline at month 12 and month 24 were imputed by control-based pattern 

imputation. 

a.  Number of women randomized 
b.  p-value < 0.001  

 

The significant difference in BMD achieved in the first 12 months was maintained through month 36 

upon transition/continuation to alendronate. Treatment differences were observed at 6 months at 

lumbar spine, total hip and femoral neck. 

 

Study 20070337 (FRAME)  

 

The efficacy and safety of romosozumab in the treatment of postmenopausal osteoporosis was 

evaluated in a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group 

study of 7,180 postmenopausal women aged 55 to 90 years (mean age of 70.9 years). 40.8% of 

enrolled women had severe osteoporosis with a prior fracture at baseline.  

 

The co-primary efficacy endpoints were the incidence of new vertebral fractures through month 12 

and through month 24.  

 

Romosozumab reduced the incidence of new vertebral fractures through month 12 (absolute risk 

reduction: 1.3% [95% CI: 0.79; 1.80], relative risk reduction: 73% [95% CI: 53; 84], adjusted p-value 

< 0.001) and after transition to denosumab through month 24 (absolute risk reduction: 1.89 % [95% 

CI: 1.30; 2.49], relative risk reduction: 75% [95% CI: 60, 84], adjusted p-value < 0.001).  

 

Women transitioning from bisphosphonate therapy 

 

Study 20080289 (STRUCTURE) 

 

The safety and efficacy of romosozumab in postmenopausal women with severe osteoporosis 

transitioning from bisphosphonate therapy (92.7% in teriparatide group and 88.1% in romosozumab 

group had prior alendronate use during the last 3 years) were evaluated in a multicenter, randomized, 

open-label study of 436 postmenopausal women aged 56 to 90 years (mean age of 71.5 years) versus 

teriparatide. 

 

The primary efficacy variable was percent change in total hip BMD from baseline at month 12. 

Romosozumab significantly increased BMD at the total hip relative to teriparatide at month 12 (mean 

treatment difference from Teriparatide: 3.4% [95% CI: 2.8; 4.0], p-value < 0.0001). The trial was not 

intended to estimate the effect on fractures but there were seven fractures in the romosozumab arm and 

nine fractures in the teriparatide arm of the study. 

 



 

Draft 

 
 

11 

Bone Histology and Histomorphometry 

 

In a bone histology sub-study, a total of 154 transiliac crest bone biopsy specimens were obtained 

from 139 postmenopausal women with osteoporosis at months 2 and 12 (in FRAME study). 

Qualitative histology assessments showed normal bone architecture and quality at all time points, 

normal lamellar bone with no evidence of mineralization defects, woven bone, marrow fibrosis, or 

clinically significant marrow abnormality in patients treated with romosozumab. 

Histomorphometry assessments on biopsies at months 2 and 12 in women showed an increase of bone 

formation parameters and a decrease in bone resorption parameters while bone volume and trabecular 

thickness were increased in romosozumab group compared to placebo group.  

 

Paediatric population 

 

The European Medicines Agency has deferred the obligation to submit the results of studies with 

romosozumab in one or more subsets of the paediatric population in the treatment of osteoporosis. 

See section 4.2 for information on paediatric use. 

 

5.2 Pharmacokinetic properties 

 

Absorption 

 

The median time to maximum romosozumab concentration (tmax) was 5 days (range: 2 to 7 days). 

Following a 210 mg subcutaneous dose, bioavailability was 81%. 

 

Biotransformation 

 

Romosozumab is a humanized monoclonal antibody (IgG2) with high affinity and specificity for 

sclerostin, and therefore is cleared via a rapid saturable elimination pathway (i.e. target mediated 

nonlinear clearance, mediated by degradation of the romosozumab-sclerostin complex) and via a slow 

nonspecific elimination pathway mediated by the reticuloendothelial system. 

 

Elimination 

 

After Cmax, serum levels declined with a mean effective half-life of 12.8 days. Steady-state was 

generally reached by month 3 with less than 2-fold accumulation following monthly dosing.  

 

Linearity/non-linearity 

 

Following subcutaneous administration, romosozumab exhibits non-linear pharmacokinetics as a 

result of binding to sclerostin. Multiple doses administered ranged from 70 to 210 mg. 

 

Renal impairment 

 

Following a 210 mg dose of romosozumab in a clinical trial of 16 patients with severe renal 

impairment (creatinine clearance < 30 ml/min) or end-stage renal disease (ESRD) receiving 

haemodialysis, mean Cmax and AUC were 29% and 44% higher in patients with severe renal 

impairment as compared to healthy subjects. Mean romosozumab exposure was similar in patients 

with ESRD receiving haemodialysis as compared to healthy subjects.  

Population pharmacokinetic analysis indicated an increase in romosozumab exposure with increasing 

severity of renal impairment. However, based on an exposure-response model of BMD changes and 

comparison to exposures obtained at tolerated clinical doses, no dose adjustment is recommended in 

these patients. Monitoring of hypocalcemia in patients with severe renal impairment or receiving 

dialysis is recommended (see section 4.4). 

 



 

Draft 

 
 

12 

Hepatic impairment 

 

No clinical trials have been conducted to evaluate the effect of hepatic impairment. Hepatic 

impairment is not expected to impact on the pharmacokinetics of romosozumab since the liver is not a 

major organ for romosozumab metabolism or excretion. 

 

Elderly  

 

The pharmacokinetics of romosozumab were not affected by age from 20 years to 89 years. 

 

Bodyweight 

 

Romosozumab exposure decreased with increasing body weight however this decrease had a minimal 

impact on lumbar spine BMD gain based on exposure-response analysis and is not clinically 

meaningful. Based on population PK analyses, the expected median steady state AUC for a 61 kg and 

114 kg patient is 558 µg.day/ml and 276 µg.day/ml respectively following a monthly subcutaneous 

dose of 210 mg romosozumab. 

 

Ethnicity and gender 

 

No dose adjustment is necessary for any patient characteristics. Based on a population 

pharmacokinetic analysis, gender and race (Japanese versus non-Japanese) had no clinically 

meaningful impact on the pharmacokinetics of romosozumab (< 20% change in exposure at steady 

state).  

 

5.3 Preclinical safety data 
 

Non-clinical data reveal no special hazard for humans based on conventional studies of safety 

pharmacology, repeated dose toxicity, carcinogenic potential or in bone safety studies. 

 

In a carcinogenicity study, doses up to 50 mg/kg/week were administered by subcutaneous injection to 

Sprague-Dawley male and female rats from 8 weeks of age for up to 98 weeks. These doses resulted in 

systemic exposures that were up to 19 times higher than the systemic exposure observed in humans 

following a monthly subcutaneous dose of 210 mg romosozumab (based on AUC comparison). 

Romosozumab caused a dose-dependent increase in bone mass with macroscopic bone thickening at 

all doses. There were no effects of romosozumab on mortality or tumor incidence in male or female 

rats.  

 

Studies in female and male rats did not show any romosozumab-related effects on mating, fertility, or 

male reproductive assessments (sperm parameters or organ weights), and there were no effects on 

estrous cycling or any ovarian or uterine parameters at exposures around 54 times the clinical 

exposure. 

 

Skeletal malformations, including syndactyly and polydactyly, were observed at a low incidence in 1 

out of 75 litters at exposures around 30 times the clinical exposure following administration of 

romosozumab to rats during the period of organogenesis. There were no adverse effects on postnatal 

growth and development.   

 

Sclerostin has been suggested to have a role in digit formation, however, as digit formation in the 

human occurs in the first trimester when placental transfer of immunoglobulins is limited, the risk of a 

similar finding in humans is low (see section 4.6).  

 

 



 

Draft 

 
 

13 

6. PHARMACEUTICAL PARTICULARS  

 

6.1 List of excipients 
 

Calcium acetate 

Glacial acetic acid 

Sodium hydroxide (for pH adjustment) 

Sucrose 

Polysorbate 20 

Water for injections 

 

6.2 Incompatibilities 

 

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 

products. 

 

6.3 Shelf life 

 

3 years. 

 

When taken out of the refrigerator for use, EVENITY should not be returned to the refrigerator but can 

be kept at room temperature (up to 25°C) for up to 30 days in the original container. If not used within 

this period, the product should be discarded.  

 

6.4 Special precautions for storage 

 

Store in a refrigerator (2°C - 8°C). Do not freeze. 

Keep the pre-filled syringe or pre-filled pen in the outer carton in order to protect from light. 

 

6.5 Nature and contents of container  

 

EVENITY 105 mg solution for injection in pre-filled pen 

 

A single use, disposable, handheld, mechanical injection device pre-assembled with pre-filled syringe  

containing 1.17 ml solution. The syringe inside the pen is made from cyclo olefin polymer plastic with 

a stopper (chlorobutyl) and insert molded stainless steel needle with elastomeric needle shield 

(synthetic rubber). 

 

Pack size of 2 pre-filled pens. 

Multipack containing 6 (3 packs of 2) pre-filled pens. 

 

EVENITY 105 mg solution for injection in pre-filled syringe  

 

A single use, disposable, pre-filled syringe containing 1.17 ml solution. The syringe is made from 

cyclo olefin polymer plastic with a stopper (chlorobutyl) and insert molded stainless steel needle and 

elastomeric needle shield (synthetic rubber).   

  

Pack size of 2 pre-filled syringes. 

Multipack containing 6 (3 packs of 2) pre-filled syringes. 

 

Not all pack sizes may be marketed. 

 

6.6 Special precautions for disposal and other handling 
 

The solution should be visually inspected for particles and discoloration prior to administration. 

EVENITY should not be used if the solution is discolored, cloudy, or contains particles. 

 



 

Draft 

 
 

14 

Prior to subcutaneous administration, romosozumab should be allowed to sit at room temperature for 

at least 30 minutes before injecting. This will help make the injection more comfortable. It should not 

be warmed in any other way. 

 

Do not shake. 

 

Any unused medicinal product or waste material should be disposed of in accordance with local 

requirements. 

 

 

7. MARKETING AUTHORISATION HOLDER 
 

UCB Pharma S.A. 

Allée de la Recherche, 60  

B-1070 Bruxelles 

Belgium 

 

 

8. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/19/1411/001 

EU/1/19/1411/002 

EU/1/19/1411/003 

EU/1/19/1411/004 

 

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 

 

 

10. DATE OF REVISION OF THE TEXT 

 

Detailed information on this medicinal product is available on the website of the European Medicines  

Agency http://www.ema.europa.eu 

 

 

 

 

http://www.ema.europa.eu/


 

Draft 

 
 

15 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX II 

 

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 

MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 



 

Draft 

 
 

16 

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 

MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 

 

Name and address of the manufacturer of the biological active substance 

Immunex Rhode Island Corporation 

40 Technology Way, West Greenwich 

Rhode Island 02817 

United States 

 

Name and address of the manufacturer responsible for batch release 

Amgen Europe B.V. 

Minervum 7061 

NL-4817 ZK Breda 

NETHERLANDS 

 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

 

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product 

Characteristics, section 4.2). 

 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION  

 

 Periodic safety update reports  

 

The requirements for submission of periodic safety update reports for this medicinal product are set 

out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 

2001/83/EC and any subsequent updates published on the European medicines web-portal. 

The marketing authorisation holder shall submit the first periodic safety update report for this 

product within 6 months following authorisation. 

 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 

 Risk Management Plan (RMP) 

 

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the 

agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreeed subsequent 

updates of the RMP. 

An updated RMP should be submitted: 

 At the request of the European Medicines Agency; 

 Whenever the risk management system is modified, especially as the result of new 

information being received that may lead to a significant change to the benefit/risk profile or 

as the result of an important (pharmacovigilance or risk minimisation) milestone being 

reached.  

 

 Additional risk minimisation measures 

 

The MAH shall ensure that the educational programme is implemented for the authorised indications 

of treatment of severe osteoporosis in postmenopausal women at high risk of fracture.  



 

Draft 

 
 

17 

The educational program is aimed at further minimizing the risks of serious cardiovascular events of 

myocardial infarction (MI) and stroke, hypocalcaemia, and of osteonecrosis of the jaw (ONJ) by 

reinforcing the key safety information available in the SmPC and the PIL. 

The educational programme contains the following:  

 Physician educational material  

 Patient alert card 

The physician educational material should contain the following key elements:  

 The Summary of Product Characteristics 

 Prescriber Guide: 

o Relevant information to support healthcare professionals (HCPs) in the appropriate 

recognition, monitoring and management of the important identified risks of serious 

cardiovascular (CV) events of MI and stroke and of hypocalcaemia and important 

potential risk of ONJ. 

o A reminder list of risk minimization actions to be performed prior to prescription of 

romosozumab. 

o A checklist, which reminds the prescriber to verify the contraindication and perform a 

careful assessment of the cardiovascular risk profile before prescribing romosozumab. 

o Instruction for a prompt medical evaluation for patients who develop symptoms 

suggestive of MI or stroke, which will enable a rapid re-assessment of the benefit-risk, 

leading to the appropriate actions regarding romosozumab treatment. 

o A reminder to the healthcare professional to educate the patient and/or caregiver on the 

risks, especially on the CV risk, and ensure the patient is provided with a Patient Alert 

Card. 

o Reminding need for and how to report suspected adverse reactions. 

The patient alert card should be provided and contain the following key messages: 

 Signs and/or symptoms of the safety concerns of serious cardiovascular events of MI and 

stroke, hypocalcaemia, and ONJ and when to seek attention from a healthcare professional. 

 Providing a reminder to the patient/caregiver to share information on history of MI or stroke 

and other CV conditions/risk factors to the osteoporosis specialist. 

 The importance of carrying the Patient Alert Card at all times and showing it to all healthcare 

professionals. 

 Administration dates of romosozumab and contact details of the prescribing physician to be 

contacted for advice if needed. 

 Important information for other healthcare professionals relevant to the patient taking 

romosozumab, including for the important identified risks of serious cardiovascular events of 

MI and stroke and of hypocalcaemia and important potential risk of ONJ. 

 Reminding the need to report side effects by patients, caregivers, or any other HCP.  
 



 

Draft 

 
 

18 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX III 

 

LABELLING AND PACKAGE LEAFLET 

 

 



 

Draft 

 
 

19 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A. LABELLING 
 

 



 

Draft 

 
 

20 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

PRE-FILLED PEN CARTON 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

EVENITY 105 mg solution for injection in pre-filled pen  

romosozumab 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each pre-filled pen contains 105 mg of romosozumab in 1.17 ml of solution (90mg/ml). 

 

 

3. LIST OF EXCIPIENTS 

 

Excipients: calcium acetate, glacial acetic acid, sodium hydroxide, sucrose, polysorbate 20 and water 

for injections 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

2 single-use pre-filled pens  

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

For subcutaneous use. 

Read the package leaflet before use. 

Do not shake. 

 

Picture on the front of the carton:  

 

 
+ 

 

 
 
 
 

= 1 dose 

 
Picture and text inside the box, visible upon opening:  

To receive full dose, take two. 

Read the package leaflet before use. 

 

 
+ 

 

 
 
 
 

= 1 dose 

 



 

Draft 

 
 

21 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Store in a refrigerator.  

Do not freeze. 

Keep the pen in the outer carton in order to protect from light. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

UCB Pharma S.A. (logo) 

Allée de la Recherche 60 

B-1070 Bruxelles 

Belgium 

 

 

12. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/19/1411/001 

EU/1/19/1411/002 

EU/1/19/1411/003 

EU/1/19/1411/004 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 



 

Draft 

 
 

22 

16. INFORMATION IN BRAILLE 

 

EVENITY 105 mg 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

2D barcode carrying the unique identifier included. 

 

 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 

PC:  

SN:  

NN:  



 

Draft 

 
 

23 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

OUTER CARTON OF MULTIPACK (WITH BLUEBOX) 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

EVENITY105 mg solution for injection in pre-filled pen  

romosozumab 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each pre-filled pen contains 105 mg of romosozumab in 1.17 ml of solution (90mg/ml). 

 

 

3. LIST OF EXCIPIENTS 

 

Excipients: calcium acetate, glacial acetic acid, sodium hydroxide, sucrose, polysorbate 20 and water 

for injections 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

Multipack: 6 (3 packs of 2) single-use pre-filled pens 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

For subcutaneous use. 

Read the package leaflet before use. 

Do not shake. 

 

Picture on the front of the carton:  

 

 
+ 

 

 
 
 
 

= 1 dose 

 
 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 



 

Draft 

 
 

24 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Store in a refrigerator. 

Do not freeze. 

Keep the pen in the outer carton in order to protect from light. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

UCB Pharma S.A. (logo) 

Allée de la Recherche 60 

B-1070 Bruxelles 

Belgium 

 

 

12. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/19/1411/001 

EU/1/19/1411/002 

EU/1/19/1411/003 

EU/1/19/1411/004 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

EVENITY 105 mg 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

2D barcode carrying the unique identifier included. 

 

 



 

Draft 

 
 

25 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 

PC:  

SN:  

NN:  

 

 



 

Draft 

 
 

26 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

INTERMEDIATE CARTON WITHIN MULTIPACK (WITHOUT BLUEBOX) 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

EVENITY 105 mg solution for injection in pre-filled pen  

romosozumab 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each pre-filled pen contains 105 mg of romosozumab in 1.17 ml of solution (90mg/ml). 

 

 

3. LIST OF EXCIPIENTS 

 

Excipients: calcium acetate, glacial acetic acid, sodium hydroxide, sucrose, polysorbate 20 and water 

for injections 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

2 single-use pre-filled pens. Component of a multipack, can’t be sold separately. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

For subcutaneous use. 

Read the package leaflet before use. 

Do not shake. 

 

Picture on the front of the carton:  

 

 
+ 

 

 
 
 
 

= 1 dose 

 
Picture and text inside the box, visible upon opening:  

To receive full dose, take two. 

Read the package leaflet before use. 

 

 
+ 

 

 
 
 
 

= 1 dose 

 



 

Draft 

 
 

27 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Store in a refrigerator. 

Do not freeze. 

Keep the pen in the outer carton in order to protect from light. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

UCB Pharma S.A. (logo) 

Allée de la Recherche 60 

B-1070 Bruxelles 

Belgium 

 

 

12. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/19/1411/001 

EU/1/19/1411/002 

EU/1/19/1411/003 

EU/1/19/1411/004 

 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 



 

Draft 

 
 

28 

16. INFORMATION IN BRAILLE 

 

EVENITY 105 mg 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 



 

Draft 

 
 

29 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

PRE-FILLED PEN LABEL  

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 

 

EVENITY 105 mg injection  

romosozumab 

SC 

 

 

2. METHOD OF ADMINISTRATION 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

1.17 ml 

 

 

6. OTHER 

 

UCB Pharma S.A. (logo) 

 

 



 

Draft 

 
 

30 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

PRE-FILLED SYRINGE CARTON 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

EVENITY 105 mg solution for injection in pre-filled syringe  

romosozumab 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each pre-filled syringe contains 105 mg of romosozumab in 1.17 ml of solution (90mg/ml). 

 

 

3. LIST OF EXCIPIENTS 

 

Excipients: calcium acetate, glacial acetic acid, sodium hydroxide, sucrose, polysorbate 20 and water 

for injections 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

2 single-use pre-filled syringes  

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

For subcutaneous use. 

Read the package leaflet before use. 

Do not shake. 

 

Picture on the front of the carton:  

 

 

 

+ 

 

 
 

= 1 dose 

 
 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 



 

Draft 

 
 

31 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Store in a refrigerator. 

Do not freeze. 

Keep the pre-filled syringe in the outer carton in order to protect from light.  

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

UCB Pharma S.A. (logo) 

Allée de la Recherche 60 

B-1070 Bruxelles 

Belgium 

 

 

12. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/19/1411/001 

EU/1/19/1411/002 

EU/1/19/1411/003 

EU/1/19/1411/004 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

EVENITY 105 mg 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

2D barcode carrying the unique identifier included. 

 

 



 

Draft 

 
 

32 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 

PC:  

SN:  

NN:  

 



 

Draft 

 
 

33 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

OUTER CARTON OF MULTIPACK (WITH BLUEBOX) 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

EVENITY 105 mg solution for injection in pre-filled syringe  

romosozumab 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each pre-filled syringe contains 105 mg of romosozumab in 1.17 ml of solution (90 mg/ml). 

 

 

3. LIST OF EXCIPIENTS 

 

Excipients: calcium acetate, glacial acetic acid, sodium hydroxide, sucrose, polysorbate 20 and water 

for injections 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

Multipack: 6 (3 packs of 2) single-use pre-filled syringes 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

For subcutaneous use. 

Read the package leaflet before use. 

Do not shake. 

 

Picture on the front of the carton:  

 

 

 

+ 

 

 
 

= 1 dose 

 
 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 



 

Draft 

 
 

34 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Store in a refrigerator. 

Do not freeze. 

Keep the syringe in the outer carton in order to protect from light. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

UCB Pharma S.A. (logo) 

Allée de la Recherche 60 

B-1070 Bruxelles 

Belgium 

 

 

12. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/19/1411/001 

EU/1/19/1411/002 

EU/1/19/1411/003 

EU/1/19/1411/004 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

EVENITY 105 mg 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

2D barcode carrying the unique identifier included. 

 

 



 

Draft 

 
 

35 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 

PC:  

SN:  

NN:  



 

Draft 

 
 

36 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

INTERMEDIATE CARTON WITHIN MULTIPACK  (WITHOUT BLUEBOX) 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

EVENITY 105 mg solution for injection in pre-filled syringe  

romosozumab 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each pre-filled syringe contains 105 mg of romosozumab in 1.17 ml of solution (90 mg/ml).. 

 

 

3. LIST OF EXCIPIENTS 

 

Excipients: calcium acetate, glacial acetic acid, sodium hydroxide, sucrose, polysorbate 20 and water 

for injections 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

2 single-use pre-filled syringes. Component of a multipack, can’t be sold separately. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

For subcutaneous use. 

Read the package leaflet before use. 

Do not shake. 

 

Picture on the front of the carton:  

 

 

 

+ 

 

 
 

= 1 dose 

 
 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 



 

Draft 

 
 

37 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Store in a refrigerator. 

Do not freeze. 

Keep the syringe in the outer carton in order to protect from light. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

UCB Pharma S.A. (logo) 

Allée de la Recherche 60 

B-1070 Bruxelles 

Belgium 

 

 

12. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/19/1411/001 

EU/1/19/1411/002 

EU/1/19/1411/003 

EU/1/19/1411/004 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

EVENITY 105 mg 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 



 

Draft 

 
 

38 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

PRE-FILLED SYRINGE LABEL  

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 

 

EVENITY 105 mg injection  

romosozumab 

SC 

 

 

2. METHOD OF ADMINISTRATION 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

1.17 ml 

 

 

6. OTHER 

 

UCB Pharma S.A. (logo) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

Draft 

 
 

39 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B. PACKAGE LEAFLET 



 

Draft 

 
 

40 

Package leaflet: Information for the user 

 

EVENITY 105 mg solution for injection in pre-filled pen 

romosozumab 

 

 

This medicine is subject to additional monitoring. This will allow quick identification of new 

safety information. You can help by reporting any side effects you may get. See the end of section 4 

for how to report side effects.  

 

Read all of this leaflet carefully before you start using this medicine because it contains 

important information for you. 
- Keep this leaflet. You may need to read it again.  
- If you have any further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours. 

- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 
effects not listed in this leaflet. See section 4. 

- You will be given a patient alert card, which contains important safety information you need to 
be aware of before and during your treatment with EVENITY. 

 

What is in this leaflet 

 

1. What EVENITY is and what it is used for  

2. What you need to know before you use EVENITY  

3. How to use EVENITY  

4. Possible side effects  

5. How to store EVENITY  

6. Contents of the pack and other information 

 

 

1. What EVENITY is and what it is used for 

 

What EVENITY is 

EVENITY contains the active substance romosozumab, a medicine that helps to make the bones 

stronger, and reduce the risk of broken bones.  
 

What EVENITY is used for 

EVENITY is used to treat severe osteoporosis in women after the menopause who are at high risk of 

broken bone (fracture).  

Osteoporosis is a disease that causes your bones to become thin and fragile. Many patients with 

osteoporosis have no symptoms, but they may be at increased risk of fractures.  

 
How EVENITY works 

EVENITY is a monoclonal antibody. A monoclonal antibody is a type of protein that has been 

designed to recognize and attach to specific proteins in the body. EVENITY attaches to a protein 

called sclerostin. By attaching to and blocking the activity of sclerostin, EVENITY:  

 helps to form new bone, and 

 slows down the loss of existing bone. 
This makes the bones stronger, and lowers the risk of fractures. 

 

 



 

Draft 

 
 

41 

2. What you need to know before you use EVENITY 

 

Do not use EVENITY if 

 you are allergic to romosozumab or any of the other ingredients of this medicine (listed in 
section 6); 

 you have low levels of calcium in the blood (hypocalcaemia). Your doctor will be able to tell 
you if your levels are too low; 

 you have a history of heart attack or stroke. 
 

Do not use EVENITY if any of the above applies to you. If you are not sure, talk to your doctor or 

pharmacist before using EVENITY. 

 

Warnings and precautions  

Talk to your doctor or pharmacist and discuss your medical history before using EVENITY. 

 

Heart attack and stroke 

Heart attack and stroke have been reported in people receiving EVENITY.  

Seek medical attention straight away if you get: 

 chest pain, shortness of breath; 

 headache, numbness, or weakness in your face, arms, or legs, difficulty talking, changes in 

vision, loss of balance. 

 

Your doctor will carefully evaluate the risk of cardiovascular problems before he/she lets you start 

treatment with EVENITY. Tell your doctor if you know that you have an increased risk of 

cardiovascular problems such as established cardiovascular disease, high blood pressure, high blood 

fat levels, diabetes, smoking or kidney problems.   

 

Low levels of calcium in the blood 

EVENITY may cause low levels of calcium in your blood.  

Tell your doctor if you notice: 

 spasms, twitches, or cramps in your muscles; 

 numbness or tingling in your fingers, toes or around your mouth.  
 

Your doctor may prescribe calcium and vitamin D to help prevent low calcium levels in your blood 

before you start your treatment and while you take EVENITY. Take calcium and vitamin D as your 

doctor tells you to.  

Tell your doctor if you have or have ever had severe kidney problems, kidney failure or have needed 

dialysis as this may increase your risk of getting low blood calcium if you do not take calcium 

supplements. 
 

Serious allergic reactions 

Serious allergic reactions can happen to people who use EVENITY.  

Seek medical attention straight away if you get: 

 swelling of the face, mouth, throat, hands, feet, ankles, lower legs (angioedema), or hives; 

 acute skin eruption showing multiple round, red/pink spots with a blistering or crusting centre 

(erythema multiforme); 

 difficulty in swallowing or breathing. 
 

Problems with your mouth, teeth or jaw 

A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely 

(may affect up to 1 in 1,000 people) in patients receiving EVENITY. ONJ can also occur after 

stopping treatment. It is important to try to prevent ONJ developing, as it may be a painful condition 

that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions 

you should take. 

 



 

Draft 

 
 

42 

Before receiving EVENITY, tell your doctor or nurse if you: 

 have any problems with your mouth or teeth such as poor dental health, gum disease, or a 
planned tooth extraction; 

 do not receive routine dental care or have not had a dental check-up for a long time; 

 are a smoker (as this may increase the risk of dental problems); 

 have previously been treated with a bisphosphonate (used to treat or prevent bone disorders, 
such as osteoporosis); 

 are taking medicines called corticosteroids (such as prednisolone or dexamethasone); 

 have cancer. 

 

Your doctor may ask you to undergo a dental examination before you start treatment with EVENITY. 

 

While being treated, you should maintain good oral hygiene and receive routine dental check-ups. If 

you wear dentures, you should make sure these fit properly. If you are under dental treatment or will 

undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell 

your dentist that you are being treated with EVENITY. 

 

Contact your doctor and dentist immediately if you get any problems with your mouth or teeth such 

as: 

 loose teeth; 

 pain or swelling; 

 mouth sores that do not heal; 

 discharge. 
 

Unusual thigh bone fractures 

People who have used EVENITY rarely developed unusual fractures of the thigh bone caused by little 

or no trauma. These fracture types are often preceded by warning signs of thigh or groin pain for 

several weeks before the fracture occurs. It is not known whether EVENITY caused these unusual 

fractures. Tell your doctor or pharmacist if you get any new or unusual pains in your hip, groin or 

thigh.  
 

Children and adolescents 

The use of romosozumab in children and adolescents has not been studied and it is not approved for 

use in paediatric patients (age <18 years). 

 

Other medicines and EVENITY 

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 

medicines. 

 

Pregnancy and breast-feeding  

EVENITY is only intended to treat women after menopause.  

EVENITY should not be used by women of child-bearing potential, or when pregnant or breast-

feeding. It is not known whether EVENITY may harm an unborn or breast-fed child.  

Contact your doctor if you have any questions. 

 

Driving and using machines 
EVENITY is expected to have no effect or very little effect on the ability to drive and use machines. 

 

EVENITY contains sodium 

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say, essentially ‘sodium-

free’. 

 

 



 

Draft 

 
 

43 

3. How to use EVENITY 

 

EVENITY will be initiated and supervised by specialist physicians experienced in the management of 

osteoporosis. Always use this medicine exactly as you doctor has told you. Check with your doctor if 

you are not sure. 

The injection should only be given by a person who has been properly trained.  

 

How much to use 

 The recommended dose of EVENITY is 210 mg. 

 Since one pre-filled pen contains 105 mg of the active substance romosozumab in 1.17 ml of 
solution (90mg/ml), 2 pre-filled pens must be used for each dose. The second injection must be 

given immediately after the first one but at a different injection site.   

 Do this once every month for 12 months. 
 

How to use 

 EVENITY has to be injected under the skin (sub-cutaneous injection). 

 EVENITY should be injected in either the stomach area (abdomen) or thigh. The outer area of 
your upper arm can also be used as an injection site, but only if someone else is giving you the 

injection.   

 If the same injection area is planned to be used for the second injection, a different injection 
spot should be used.  

 EVENITY should not be injected into areas where the skin is tender, bruised, red, or hard.  

 

It is important that you read the Instructions for Use for detailed information on how to use the 

EVENITY pre-filled pen.  

 

Ask your doctor or pharmacist if you have any further questions on the use of the medicine.  

 

If you use more EVENITY than you should 

If, by mistake, you have used more EVENITY than you should, contact your doctor or pharmacist. 

 

If you forget to use or cannot take EVENITY at your usual time 

If you miss a dose of EVENITY, contact your doctor as soon as possible to schedule another dose. 

Thereafter, the next dose should be given not earlier than one month after the date of the last dose.  

 

If you stop taking EVENITY 

If you are considering stopping EVENITY treatment, please discuss this with your doctor. Your doctor 

will advise you on how long you should be treated with EVENITY. 

 

If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 

 

Discuss with your doctor the need to switch to another osteoporosis treatment after the end of your 

treatment with EVENITY. 

 

 

4. Possible side effects 

 

Like all medicines, this medicine can cause side effects, although not everybody gets them. 

 

Seek medical attention straight away if you get any of the following possible symptoms of heart 

attack or stroke (uncommon: may affect up to 1 in 100 people): 

 chest pain, shortness of breath;  

 headache, numbness, or weakness in your face, arms, or legs, difficulty talking, changes in 

vision, loss of balance. 

 



 

Draft 

 
 

44 

Seek medical attention straight away if you get the following symptoms of a serious allergic 

reaction (rare: may affect up to 1 in 1,000 people): 

 swelling of the face, mouth, throat, hands, feet, ankles, lower legs (angioedema), or hives; 

 acute skin eruption showing multiple round, red/pink spots with a blistering or crusting centre 

(erythema multiforme); 

 difficulty in swallowing or breathing. 

 

Tell your doctor if you notice the following symptoms of low levels of calcium in the blood 

(hypocalcaemia) (uncommon: may affect up to 1 in 100 people): 

 spasms, twitches, or cramps in your muscles; 

 numbness or tingling in your fingers, toes or around your mouth. 

 

See also section 2 “What you need to know before you use EVENITY”.  

 

Other side effects may include:  

 

Very common side effects (may affect more than 1 in 10 people):  

 Common cold;  

 Joint pain.  

 

Common side effects (may affect up to 1 in 10 people): 

 Rash, inflammation of the skin;  

 Headache; 

 Sinusitis; 

 Neck pain; 

 Muscle spasms; 

 Redness or pain around the site where the injection was given.  

 

Uncommon side effects (may affect up to 1 in 100 people): 

 Hives (urticaria); 

 Cataract. 

 
Reporting of side effects 

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 

not listed in this leaflet. You can also report side effects directly via the national reporting system 

listed in Appendix V. By reporting side effects you can help provide more information on the safety of 

this medicine. 

 

 

5. How to store EVENITY 
 

Keep this medicine out of the sight and reach of children. 

 

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The 

expiry date refers to the last day of that month. 

 

Store in a refrigerator (2°C - 8°C). Do not freeze. 

Once you take the carton containing the pre-filled pens out of the refrigerator for use, you should not 

put it back into the refrigerator but you can keep it at room temperature (up to 25°C) for up to 30 days. 

If not used within this period the product should be discarded. 

 

Keep the pre-filled pen in the outer carton in order to protect from light. 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

Draft 

 
 

45 

 

Visually check the solution. Do not use it if the solution is discoloured, cloudy, or contains flakes or 

particles. 

 

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 

throw away medicines you no longer use. These measures will help protect the environment. 

 

 

6. Contents of the pack and other information 

 

What EVENITY contains  

- The active substance is romosozumab. Each pre-filled pen contains 105 mg of romosozumab in 
1.17 ml of solution (90mg/ml). 

- The other ingredients are calcium acetate, glacial acetic acid, sodium hydroxide (for pH 
adjustment), sucrose, polysorbate 20 and water for injections. See section 2 “EVENITY 

contains sodium” 

 

What EVENITY looks like and contents of the pack 

EVENITY is a clear to opalescent, colourless to light yellow solution for injection provided in a single 

use disposable pre-filled pen. The syringe inside the pen is made of plastic with a stainless steel 

needle.  

 

Pack size of 2 pre-filled pens. 

Multipack containing 6 (3 packs of 2) pre-filled pens.  

Not all pack sizes may be marketed. 

 

Marketing Authorisation Holder 

UCB Pharma S.A.,  

Allée de la Recherche 60,  

B-1070 Bruxelles, Belgium 

 

Manufacturer 

Amgen Europe B.V.,  

Minervum 7061,  

4817 ZK Breda, Netherlands 

 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder.  

 

België/Belgique/Belgien 

UCB Pharma SA/NV  

Tél/Tel: + 32 / (0)2 559 92 00 

  

Lietuva 

UCB Pharma Oy Finland  

Tel: + 358 9 2514 4221  

 

България 

Ю СИ БИ България ЕООД  

Teл.: + 359 (0) 2 962 30 49 

 

Luxembourg/Luxemburg 

UCB Pharma SA/NV  

Tél/Tel: + 32 / (0)2 559 92 00 

 

Česká republika 

UCB s.r.o.  

Tel: + 420 221 773 411 

 

Magyarország 

UCB Magyarország Kft.  

Tel.: + 36-(1) 391 0060 

 

Danmark 

UCB Nordic A/S  

Tlf: + 45 / 32 46 24 00 

 

Malta 

Pharmasud Ltd.  

Tel: + 356 / 21 37 64 36 

 



 

Draft 

 
 

46 

Deutschland 

UCB Pharma GmbH  

Tel: + 49 /(0) 2173 48 4848 

 

Nederland 

UCB Pharma B.V.  

Tel.: + 31 / (0)76-573 11 40 

 

Eesti 

UCB Pharma Oy Finland   

Tel: + 358 9 2514 4221  

 

Norge 
UCB Nordic A/S  

Tlf: + 45 / 32 46 24 00 

 

Ελλάδα 
UCB Α.Ε.   

Τηλ: + 30 / 2109974000 

 

Österreich 
UCB Pharma GmbH  

Tel: + 43-(0)1 291 80 00 

 

España 

UCB Pharma, S.A.  

Tel: + 34 / 91 570 34 44 

 

Polska 

UCB Pharma Sp. z o.o.  

Tel: + 48 22 696 99 20 

 

France 

UCB Pharma S.A.  

Tél: + 33 / (0)1 47 29 44 35 

 

Portugal 
UCB Pharma (Produtos Farmacêuticos), Lda  

Tel: + 351 / 21 302 5300 

 

Hrvatska 
Medis Adria d.o.o.  

Tel: +385 (0) 1 230 34 46 

 

România 

UCB Pharma Romania S.R.L.  

Tel: + 40 21 300 29 04 

 

Ireland 
UCB (Pharma) Ireland Ltd.  

Tel: + 353 / (0)1-46 37 395 

 

Slovenija 
Medis, d.o.o.  

Tel: + 386 1 589 69 00 

 

Ísland 

Vistor hf.  

Simi: + 354 535 7000 

 

Slovenská republika 

UCB s.r.o., organizačná zložka  

Tel: + 421 (0) 2 5920 2020 

 

Italia 
UCB Pharma S.p.A.  

Tel: + 39 / 02 300 791 

 

Suomi/Finland 
UCB Pharma Oy Finland  

Puh/Tel: + 358 9 2514 4221 

 

Κύπρος 

Lifepharma (Z.A.M.) Ltd  

Τηλ: + 357 22 34 74 40   

 

Sverige 

UCB Nordic A/S  

Tel: + 46 / (0) 40 29 49 00 

 

Latvija 

UCB Pharma Oy Finland  

Tel: + 358 9 2514 4221 (Somija) 

 

United Kingdom 

UCB Pharma Ltd.  

Tel : + 44 / (0)1753 534 655 

 

This leaflet was last revised in MM/YYYY. 

 

Other sources of information 

 

Detailed information on this medicine is available on the European Medicines Agency web site: 

http://www.ema.europa.eu.  

 



 

Draft 

 
 

47 

Please turn over for the Instructions for Use. 

 

------------------------------------------------------------------------------------------------------------------------ 

 

INSTRUCTIONS FOR USE FOR THE EVENITY INJECTION BY MEANS OF A PRE-

FILLED PEN 

 

Inject two pre-filled pens one immediately after the other to get a full dose 

 

 

 
 

 

The following instructions explain how to use the pre-filled pen to inject EVENITY.  

 Please read these instructions carefully and follow them step by step.  

 If you have any questions or you feel unsure about the injection procedure, please contact a 
doctor or pharmacist.  

 It is important to make sure that the injection is only administered by an individual that has been 
properly trained.  

 The pre-filled pen is also referred to as “the medicine”. 

= 1 dose 



 

Draft 

 
 

48 

Guide to parts: pre-filled pen  
 

Before use After use 

 

 

 

 

 

 

 

 

 

 

Expiry date 

 

 

 

 

 

 

Window 

 

 

 

Medicine 

 

 

White cap on 

 

 

 

 

 

 

 

 

 

 

 

 

Expiry date 

 

 

 

 

 

Yellow window 

(injection complete) 

 

 

 

 

 

Yellow safety guard 

 

 

 

 

White cap off 

 

 

 

STOP 

 

Read this before the medicine is injected. 

Your healthcare provider has prescribed a dose of 210 mg 

every month: To receive your full dose, two 105 mg pre-

filled pens should be injected, one immediately after the 

other. 

 

 

 
+ 

 

 

 

 

 

= 1 dose 

 
 



 

Draft 

 
 

49 

Step 1:  Prepare 

A  Take the carton containing the two pre-filled pens out of the refrigerator. 

 Your pre-filled pens should be left outside the refrigerator to reach room temperature (up to 25°C) 
for at least 30 minutes before injection (do not warm in any other way). This will make the 

injection more comfortable. 

 Open the carton and gather all materials you need for the injection (as listed in Step B). 

 Wash your hands thoroughly. 

 Lift the pre-filled pens straight up out of the carton − do not remove the white caps from the pre-
filled pens yet. 

 Do not shake the pre-filled pens. 

 Check the medicine through the viewing window. The medicine should be a clear to opalescent,  
colourless to light yellow solution. 

- Do not use the pre-filled pens if the solution is discoloured, cloudy, or contains flakes or 
particles. 

- You may see air bubbles. Injecting the solution subcutaneously (under the skin) which  
contains air bubbles is harmless. 

 Do not use the pre-filled pens if: 

- it has been dropped; 
- the white cap is missing or not securely attached; 
- the seal is missing or broken or if any other part appears cracked or broken. 

In such case, use a new pen and contact your doctor as soon as possible. 

 

B On a clean, well-lit work surface, place: 

  two pre-filled pens; 

 two alcohol wipes; 

 two cotton balls or gauze pads; 

 two adhesives bandages; 

 special disposal container. 

 

 

C Prepare and clean the skin where you are going to inject the medicine. You can choose from: 

  the thighs; 

 the stomach area (abdomen), but not the 5 cm area 
around the belly button; 

 the outer area of the upper arm (if someone else is 
giving you the injection). 

 
 

 The second injection should be given on a different site than the one used for the first injection. If 
you wish to use the same injection site, make sure it is not the exact same injection spot. 

 Do not inject into areas where the skin is tender, bruised, red, hard, has scars, or stretch marks, or 
has raised thick, red, or scaly skin patches or lesions.  

 

 Clean the area you are going to inject with an alcohol wipe. Let the skin dry before the injection. 
 

Outer area of  

upper arm 

Stomach area    

(abdomen) 

Thigh 

 



 

Draft 

 
 

50 

 

 

 
 Do not touch this area again before injecting. 

 

Step 2:  Get ready 

D  Pull the white cap straight off just before the injection.  

 Once the cap is removed, the injection must be given within 5 minutes. There is no need to rush 
the injection - 5 minutes is enough time. 

  

 

 

 
 Do not twist or bend the white cap. 
 

 Discard the white cap in the special disposal container. Do not place the white cap back onto 
the pre-filled pen. 

 

 Although hidden from view, the needle tip is now uncovered. Do not try to touch the needle as 
it could activate the pre-filled pen. It is normal to see a drop of liquid at the end of the needle 

(inside the yellow safety guard). 

 

 

E Stretch or pinch the injection site to create a firm surface. 

 

 
Stretch method 

  Stretch the skin firmly by moving thumb and fingers in opposite directions, to create an area 
about 5 cm wide. 

 

 
 

OR 



 

Draft 

 
 

51 

Pinch method 

  Pinch the skin firmly between thumb and fingers, to create an area about 5 cm wide. 

 

 
 

 Important: Keep the skin stretched or pinched while injecting. 
 

 

Step 3:  Inject 

F  Important: The pre-filled pen should not be pushed down until the actual injection is ready to 
be performed. 

 The stretch or pinch should be held. With the other hand, the pre-filled pen’s yellow safety 
guard should be placed down on the area of the skin that previously has been cleaned (the 

“injection site”) at a 90° degree angle. 

 

 

Yellow safety guard 

 

G  The pre-filled pen should be firmly pushed down onto the skin until the yellow safety guard 
stops moving. When you hear or feel a click, the injection will begin. 

H  Keep pushing down on the skin. The injection could take about 15 seconds. 

 When the injection is complete, the viewing window will turn fully yellow and you may also 
hear or feel a second click.  

 

 



 

Draft 

 
 

52 

Push down 

 

 

 

 
 

 

 

15 seconds 

 

 

 

Window turns fully yellow when injection is 

complete. 

 

   The used pre-filled pen may now be removed by carefully pulling it straight up from the skin. 

 Important: When you remove the pre-filled pen, if the window has not turned fully yellow, or if 
it looks like the medicine is still injecting, this means the full dose has not been delivered. Your 

healthcare provider should be informed as soon as possible. 

  After removing the pre-filled pen from the skin, the 
needle will be automatically covered. Do not try to 

touch the needle. 

 

 

 

Step 4:  Dispose 

I  Discard the entire used pre-filled pen and the white cap in 
a special container straight away after use. 

 

 

 
 Do not throw away (dispose of) the pre-filled pen in the household waste. 

 Do not re-use the pre-filled pen. 

 Important: Always keep the special disposal container out of the sight and reach of children. 
 

“click” 

“click” 



 

Draft 

 
 

53 

Step 5:  Examine the injection site 

J If there is blood, use a cotton ball or a piece of gauze and apply light pressure over the injection site for 

a few seconds. Do not rub the injection site. The injection site can be covered with a small adhesive 

bandage, if necessary. 

 

Step 6:  Repeat for the second injection to get the full dose 

K Repeat all steps starting from step C with the second pre-filled pen to inject the full dose. The second 

injection should be given on a different site than the one used for the first injection. If you wish to use 

the same injection site, make sure it is not the exact same injection spot. 

 

 

 

 
+ 

 

 

 

 

 

= 1 dose 

 
 

 

 

 

 



 

Draft 

 
 

54 

Package leaflet: Information for the user 

 

EVENITY 105 mg solution for injection in a pre-filled syringe 

romosozumab 

 

This medicine is subject to additional monitoring. This will allow quick identification of new 

safety information. You can help by reporting any side effects you may get. See the end of section 4 

for how to report side effects. 

 

Read all of this leaflet carefully before you start using this medicine because it contains 

important information for you. 

- Keep this leaflet. You may need to read it again.  
- If you have any further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours.  

- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 
effects not listed in this leaflet. See section 4. 

- You will be given a patient alert card, which contains important safety information you need to be 
aware of before and during your treatment with EVENITY. 

 

What is in this leaflet 

 

1. What EVENITY is and what it is used for  

2. What you need to know before you use EVENITY  

3. How to use EVENITY  

4. Possible side effects  

5. How to store EVENITY 

6. Contents of the pack and other information 

 

 

1. What EVENITY is and what it is used for 

 

What EVENITY is 

EVENITY contains the active substance romosozumab, a medicine that helps to make the bones 

stronger, and reduce the risk of broken bones.  

 

What EVENITY is used for 

EVENITY is used to treat severe osteoporosis in women after the menopause who are at high risk of 

broken bone (fracture).  

Osteoporosis is a disease that causes your bones to become thin and fragile. Many patients with 

osteoporosis have no symptoms, but they may be at increased risk of fractures.  
 

How EVENITY works 

EVENITY is a monoclonal antibody. A monoclonal antibody is a type of protein that has been 

designed to recognize and attach to specific proteins in the body. EVENITY attaches to a protein 

called sclerostin. By attaching to and blocking the activity of sclerostin, EVENITY:  

 helps to form new bone, and 

 slows down the loss of existing bone. 
This makes the bones stronger, and lowers the risk of fractures. 

 

 



 

Draft 

 
 

55 

2. What you need to know before you use EVENITY  
 

Do not use EVENITY if: 

 you are allergic to romosozumab or any of the other ingredients of this medicine (listed in 
section 6); 

 you have low levels of calcium in the blood (hypocalcaemia). Your doctor will be able to tell 
you if your levels are too low; 

 you have history of heart attack or stroke. 
 

Do not use EVENITY if any of the above applies to you. If you are not sure, talk to your doctor or 

pharmacist before using EVENITY. 

 

Warnings and precautions  

Talk to your doctor or pharmacist and discuss your medical history before using EVENITY. 

 

Heart attack and stroke 

Heart attack and stroke have been reported in people receiving EVENITY.  

Seek medical attention straight away if you get: 

 chest pain, shortness of breath; 

 headache, numbness, or weakness in your face, arms, or legs, difficulty talking, changes in 
vision, loss of balance. 

 

Your doctor will carefully evaluate the risk of cardiovascular problems before he/she lets you start 

treatment with EVENITY. Tell your doctor if you know that you have an increased risk of 

cardiovascular problems such as established cardiovascular disease, high blood pressure, high blood 

fat levels, diabetes, smoking or kidney problems.   

 

Low levels of calcium in the blood 

EVENITY may cause low levels of calcium in your blood.  

Tell your doctor if you notice: 

 spasms, twitches, or cramps in your muscles;  

 numbness or tingling in your fingers, toes or around your mouth.  
 

Your doctor may prescribe calcium and vitamin D to help prevent low calcium levels in your blood 

before you start your treatment and while you take EVENITY. Take calcium and vitamin D as your 

doctor tells you to. Tell your doctor if you have or have ever had severe kidney problems, kidney 

failure or have needed dialysis as this may increase your risk of getting low blood calcium if you do 

not take calcium supplements.  

 

Serious allergic reactions 

Serious allergic reactions can happen to people who use EVENITY.  

Seek medical attention straight away if you get: 

 swelling of the face, mouth, throat, hands, feet, ankles, lower legs (angioedema), or hives; 

 acute skin eruption showing multiple round, red/pink spots with a blistering or crusting centre 

(erythema multiforme); 

 difficulty in swallowing or breathing. 
 

Problems with your mouth, teeth or jaw 

A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely 

(may affect up to 1 in 1,000 people) in patients receiving EVENITY. ONJ can also occur after 

stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition 

that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions 

you should take. 



 

Draft 

 
 

56 

Before receiving EVENITY, tell your doctor or nurse if you: 

 have any problems with your mouth or teeth such as poor dental health, gum disease, or a 
planned tooth extraction; 

 do not receive routine dental care or have not had a dental check-up for a long time; 

 are a smoker (as this may increase the risk of dental problems); 

 have previously been treated with a bisphosphonate (used to treat or prevent bone disorders, 
such as osteoporosis); 

 are taking medicines called corticosteroids (such as prednisolone or dexamethasone); 

 have cancer. 

 

Your doctor may ask you to undergo a dental examination before you start treatment with EVENITY. 

 

While being treated, you should maintain good oral hygiene and receive routine dental check-ups. If 

you wear dentures, you should make sure these fit properly. If you are under dental treatment or will 

undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell 

your dentist that you are being treated with EVENITY. 

Contact your doctor and dentist immediately if you get any problems with your mouth or teeth such 

as: 

 loose teeth; 

 pain or swelling; 

 mouth sores that do not heal; 

 discharge. 

 

Unusual thigh bone fractures 

People who have used EVENITY, rarely developed unusual fractures of the thigh bone  caused by 

little or no trauma. These fracture types are often proceded by warning signs of thigh or groin pain for 

several weeks before the fracture occurs. It is not known whether EVENITY caused these unusual 

fractures. Tell your doctor or pharmacist if you get any new or unusual pains in your hip, groin or 

thigh.  

 

Children and adolescents 

The use of EVENITY in children and adolescents has not been studied.  

 

Other medicines and EVENITY 

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 

medicines.  

 

Pregnancy and breast-feeding  

EVENITY is only intended to treat women after menopause.  

EVENITY should not be used by women of child-bearing potential, or when pregnant or breast-

feeding. It is not known whether EVENITY may harm an unborn or breast-fed child.  

Contact your doctor if you have any questions. 

 

Driving and using machines 
EVENITY is expected to have no effect or very little effect on the ability to drive and use machines. 

 

EVENITY contains sodium 

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium- 

free’. 

 

 



 

Draft 

 
 

57 

3. How to use EVENITY 

  

EVENITY will be initiated and supervised by specialist physicians experienced in the management of 

osteoporosis. Always use this medicine exactly as you doctor has told you. Check with your doctor if 

you are not sure. 

The injection should only be given by a person who has been properly trained.  

 

How much to use 

 The recommended dose of EVENITY is 210 mg. 

 Since one pre-filled syringe contains 105 mg of the active substance romosozumab, 2 pre-filled 
syringes must be used for each dose. The second injection must be given immediately after the 

first one but at a different injection site.   

 Do this once every month for 12 months.  
 

How to use 

 EVENITY has to be injected under the skin (sub-cutaneous injection). 

 EVENITY should be injected in either the stomach area (abdomen) or thigh. The outer area of 
your upper arm can also be used as an injection site, but only if someone else is giving you the 

injection.   

 If the same injection area is planned to be used for the second injection, a different injection 
spot should be used.  

 EVENITY should not be injected into areas where the skin is tender, bruised, red, or hard.  

 

It is important that you read the Instructions for Use for detailed information on how to use the 

EVENITY pre-filled syringe.  

 

Ask your doctor or pharmacist if you have any further questions on the use of the medicine.  

 

If you use more EVENITY than you should 

If, by mistake, you have used more EVENITY than you should, contact your doctor or pharmacist. 

 

If you forget to use or cannot take EVENITY at your usual time 
If you miss a dose of EVENITY, contact your doctor as soon as possible to schedule another dose. 

Thereafter, the next dose should be given not earlier than one month after the date of the last dose.  

 

If you stop taking EVENITY 

If you are considering stopping EVENITY treatment, please discuss this with your doctor. Your doctor 

will advise you on how long you should be treated with EVENITY. 

 

If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 

 

Discuss with your doctor the need to switch to another osteoporosis treatment after the end of your 

treatment with EVENITY. 

 

 

4. Possible side effects 

 

Like all medicines, this medicine can cause side effects, although not everybody gets them.  

 

Seek medical attention straight away if you get the following possible symptoms of heart attack or 

stroke (uncommon: may affect up to 1 in 100 people): 

 chest pain, shortness of breath; 

 headache, numbness, or weakness in your face, arms, or legs, difficulty talking, changes in 

vision, loss of balance. 

 



 

Draft 

 
 

58 

Seek medical attention straight away if you get the following symptoms of serious allergic 

reaction (rare: may affect up to 1 in 1,000 people): 

 swelling of the face, mouth, throat, hands, feet, ankles, lower legs (angioedema), or hives; 

 acute skin eruption showing multiple round, red/pink spots with a blistering or crusting centre 
(erythema multiforme); 

 difficulty in swallowing or breathing. 
 

Tell your doctor if you notice the following symptoms of low levels of calcium in the blood 

(hypocalcaemia) (uncommon: may affect up to 1 in 100 people): 

 spasms, twitches, or cramps in your muscles; 

 numbness or tingling in your fingers, toes or around your mouth. 
 

See also section 2 “What you need to know before you use EVENITY”.  

 

Other side effects may include:  

 

Very common side effects (may affect more than 1 in 10 people):  

 Common cold; 

 Joint pain. 
 

Common side effects (may affect up to 1 in 10 people): 

 Rash, inflammation of the skin; 

 Headache; 

 Sinusitis; 

 Neck pain; 

 Muscle spasms; 

 Redness or pain around the site where the injection was given. 
 

Uncommon side effects (may affect up to 1 in 100 people): 

 Hives (urticaria); 

 Cataract. 

 

Reporting of side effects 

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 

not listed in this leaflet. You can also report side effects directly via the national reporting system 

listed in Appendix V. By reporting side effects you can help provide more information on the safety of 

this medicine. 

 

 

5. How to store EVENITY 
 

Keep this medicine out of the sight and reach of children. 

 

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The 

expiry date refers to the last day of that month. 

 

Store in a refrigerator (2°C - 8°C). Do not freeze. 

Once you take the carton containing the pre-filled syringes out of the refrigerator for use, you should 

not put it back into the refrigerator but you can keep it at room temperature (up to 25°C) for up to 

30 days. If not used within this period the product should be discarded. 

 

Keep the pre-filled syringe in the outer carton in order to protect from light. 

 

Visually check the solution. Do not use it if the solution is discoloured, cloudy, or contains flakes or 

particles. 

 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

Draft 

 
 

59 

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 

throw away medicines you no longer use. These measures will help protect the environment. 

 

 

6. Contents of the pack and other information 

 

What EVENITY contains  

 The active substance is romosozumab. Each pre-filled syringe contains 105 mg of 
romosozumab in 1.17 ml of solution (90 mg/ml).  

 The other ingredients are calcium acetate, glacial acetic acid, sodium hydroxide (for pH 
adjustment), sucrose, polysorbate 20 and water for injections. See section 2 “EVENITY 

contains sodium.” 

 

What EVENITY looks like and contents of the pack 

EVENITY is a clear to opalescent, colourless to light yellow solution for injection provided in a single 

use disposable pre-filled syringe. The syringe is made of plastic with a stainless steel needle.  

 

Pack size of 2 pre-filled syringes. 

Multipack containing 6 (3 packs of 2) pre-filled syringes.  

Not all pack sizes may be marketed. 

 

Marketing Authorisation Holder 

UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium  

 

Manufacturer: 

Amgen Europe B.V., Minervum 7061, 4817 ZK Breda, Netherlands 

 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder.  

 

België/Belgique/Belgien 
UCB Pharma SA/NV  

Tél/Tel: + 32 / (0)2 559 92 00 

 

Lietuva 
UCB Pharma Oy Finland  

Tel: + 358 9 2514 4221  

България 

Ю СИ БИ България ЕООД  

Teл.: + 359 (0) 2 962 30 49 

 

Luxembourg/Luxemburg 
UCB Pharma SA/NV  

Tél/Tel: + 32 / (0)2 559 92 00 

 

Česká republika 

UCB s.r.o.  

Tel: + 420 221 773 411 

Magyarország 

UCB Magyarország Kft.  

Tel.: + 36-(1) 391 0060 

 

Danmark 
UCB Nordic A/S  

Tlf: + 45 / 32 46 24 00 

 

Malta 

Pharmasud Ltd.  

Tel: + 356 / 21 37 64 36 

 

Deutschland 
UCB Pharma GmbH  

Tel: + 49 /(0) 2173 48 4848 

 

Nederland 
UCB Pharma B.V.  

Tel.: + 31 / (0)76-573 11 40 

 

Eesti 

UCB Pharma Oy Finland   

Tel: + 358 9 2514 4221  

 

Norge 
UCB Nordic A/S  

Tlf: + 45 / 32 46 24 00 

 



 

Draft 

 
 

60 

Ελλάδα 
UCB Α.Ε.   

Τηλ: + 30 / 2109974000 

 

Österreich 
UCB Pharma GmbH  

Tel: + 43-(0)1 291 80 00 

 

España 

UCB Pharma, S.A.  

Tel: + 34 / 91 570 34 44 

 

Polska 

UCB Pharma Sp. z o.o.  

Tel: + 48 22 696 99 20 

 

France 

UCB Pharma S.A.  

Tél: + 33 / (0)1 47 29 44 35 

 

Portugal 
UCB Pharma (Produtos Farmacêuticos), Lda  

Tel: + 351 / 21 302 5300 

 

Hrvatska 
Medis Adria d.o.o.  

Tel: +385 (0) 1 230 34 46 

 

România 

UCB Pharma Romania S.R.L.  

Tel: + 40 21 300 29 04 

 

Ireland 
UCB (Pharma) Ireland Ltd.  

Tel: + 353 / (0)1-46 37 395 

 

Slovenija 
Medis, d.o.o.  

Tel: + 386 1 589 69 00 

 

Ísland 

Vistor hf.  

Simi: + 354 535 7000 

 

Slovenská republika 

UCB s.r.o., organizačná zložka  

Tel: + 421 (0) 2 5920 2020 

 

Italia 
UCB Pharma S.p.A.  

Tel: + 39 / 02 300 791 

 

Suomi/Finland 
UCB Pharma Oy Finland  

Puh/Tel: + 358 9 2514 4221 

 

Κύπρος 

Lifepharma (Z.A.M.) Ltd  

Τηλ: + 357 22 34 74 40   

 

Sverige 

UCB Nordic A/S  

Tel: + 46 / (0) 40 29 49 00 

 

Latvija 

UCB Pharma Oy Finland  

Tel: + 358 9 2514 4221 (Somija) 

 

United Kingdom 

UCB Pharma Ltd.  

Tel : + 44 / (0)1753 534 655 

 

 

This leaflet was last revised in MM/YYYY. 
 

Other sources of information 

 

Detailed information on this medicine is available on the European Medicines Agency web site: 

http://www.ema.europa.eu.  



 

Draft 

 
 

61 

Please turn over for the Instructions for Use. 

------------------------------------------------------------------------------------------------------------------------ 

 

INSTRUCTIONS FOR USE FOR THE EVENITY INJECTION BY MEANS OF A PRE-

FILLED SYRINGE 

 

Inject two pre-filled syringes one immediately after the other to get a full dose 

 

 

 
+ 

 

 
 

= 1 dose 

 

The following instructions explain how to use the pre-filled syringe to inject EVENITY.  

• Please read these instructions carefully and follow them step by step.  

• If you have any questions or you feel unsure about the injection procedure, please contact a 
doctor or pharmacist.  

• It is important to make sure that the injection is only administered by an individual that has been 
properly trained.  

• The pre-filled syringe is also referred to as “the medicine”. 

 

Guide to parts: pre-filled syringe 

 

Plunger  

rod 

Finger 

flange 

Label and 
expiration  

date 

Syringe 

barrel 

Medicine 

Gray 

needle 

cap on 

Used 
plunger  

rod 

Finger  

flange 

Label and 

Expiration 

date 

Used 
syringe  

barrel 

Used  

needle 

Gray 

needle 

cap off 

Before use After use 



 

Draft 

 
 

62 

 

 

STOP 

 

Read this before the medicine is injected. 

Your healthcare provider has prescribed a dose of 

210 mg every month dose: To receive your full dose, 

two 105 mg pre-filled syringes should be injected, 

one immediately after the other. 

  

 

 

+ 

 

 
 

= 1 dose 

 

Step 1:  Prepare 

 

A  Take the carton containing the two pre-filled syringes out of the refrigerator. 

 Your pre-filled syringes should be left outside the refrigerator to reach room temperature (up to 
25°C) for at least 30 minutes before injection (do not warm in any other way). This will make 

the injection more comfortable. 

 

 Open the carton and gather all the materials you need for the injection (as listed in Step B). 
 

 Wash your hands thoroughly. 
 

 Remove two pre-filled syringes from the carton as shown in the picture. 

 

 Important: Always hold the pre-filled syringes by the syringe barrel. 
 

 Place finger or thumb on edge of tray to secure it while you remove the pre-filled syringes.  
 

 Grab the syringe barrel to remove the pre-filled syringes from the tray. 

 
 

 
 Do not grasp the plunger rod or the grey needle cap. 
 

 Do not remove the grey cap from the pre-filled syringes yet. 
 

 Do not remove the finger flange. This is part of the pre-filled syringe. 
 

 Do not shake the pre-filled syringes. 
 

 Check the medicine in the syringes. The medicine should be a clear to opalescent, colourless to 
light yellow solution. 

-  Do not use the pre-filled syringes if the solution is discoloured, cloudy, or contains flakes 
or particles. 

-  You may see air bubbles. Injecting the solution subcutaneously (under the skin) which 
contains air bubbles is harmless. 

Grab Here 



 

Draft 

 
 

63 

  Do not use the pre-filled syringe if: 
-  it has been dropped; 
-  if the grey needle cap is missing or not securely attached; 
-  if the seal is missing or broken or if any part appears cracked or broken. 

In such case, use a new syringe and contact your doctor as soon as possible.  

 

B On a clean, well-lit work surface, place: 

  two pre-filled syringes; 

 two alcohol wipes; 

 two cotton balls or gauze pads; 

 two adhesives bandages; 

 special disposal container. 

 
 

 

C Prepare and clean the skin where you are going to inject the medicine. You can choose from: 

  

 the thighs; 

 the stomach area (abdomen), but not the 5 cm area 
around the belly button; 

 the outer area of the upper arm (if someone else is 
giving you the injection). 

  

  
  The second injection should be given on a different site than the one used for the first injection. If 

you wish to use the same injection site, make sure it is not the exact same injection spot. 

 

 Do not inject into areas where the skin is tender, bruised, red, hard, has scars, or stretch marks, or 
has raised thick, red, or scaly skin patches or lesions 

 

 Clean the area you are going to inject with an alcohol wipe. Let the skin dry before the injection. 

 

 Do not touch this area again before injecting. 
 

Step 2:  Get ready 

D  Pull the grey needle cap straight off and away from the body just before the injection.  

- Take care not to touch the needle or let the needle touch any surface.  

 Once the cap is removed, the injection must be given within 5 minutes. There is no need to rush 
the injection - 5 minutes is enough time. 

- It is normal to see a drop of liquid at the end of the needle. 

Outer area of  
upper arm 

Stomach area    

(abdomen) 

Thigh 

 



 

Draft 

 
 

64 

 

 

 
 Do not twist or bend the grey needle cap. 

 

 Discard the grey needle cap in the special disposal container. Do not place the grey needle cap 
back onto the pre-filled syringe. 

 

 

E  Pinch skin firmly between your thumb and fingers, creating a firm surface about 5 cm wide. 

 

 
 

  Important: Keep the skin pinched while injecting. 
 

 

Step 3:  Inject 

F  Important: The plunger rod should not be pushed down until the actual injection is ready to be 
performed. 

 

 The pinch should be held. With the other hand, the pre-filled syringe’s needle should be inserted 
into the area of the skin that previously has been cleaned (the “injection site”) at a 45 to 

90° degree angle. 

 

 Finger should not be placed on the plunger rod while inserting the needle. 

 

 

 

 



 

Draft 

 
 

65 

G  Using slow and constant pressure, push the plunger rod all the way down until it stops moving 
indicating the entire dose has been delivered. The pre-filled syringe should be kept in the skin 

while completing the dose delivery. 

 
 

 
 

 

H  Once complete, release your thumb and gently lift the pre-filled syringe off the skin at the same 
angle at which it was inserted. 

- After you remove the pre-filled syringe from the skin, the syringe barrel should be empty. 

 

 

  Important: If it looks like the medicine is still in the syringe barrel, this means you have not 
delivered a full injection. Your healthcare provider should be informed as soon as possible. 

 

 

Step 4:  Dispose 

I  Discard the entire used pre-filled syringe and the grey needle 
cap in a special container straight away after use. 

 

 

 
 Do not throw away (dispose of) the pre-filled syringe in the household waste. 

 

 Do not re-use the pre-filled syringe. 
 

 Important: Always keep the special disposal container out of the sight and reach of children. 
 

 

Step 5:  Examine the injection site 

J If there is blood, use a cotton ball or piece of gauze and apply light pressure over the injection site 

for a few seconds. Do not rub the injection site. The injection site can be covered with a small 

adhesive bandage, if necessary. 

 



 

Draft 

 
 

66 

 

Step 6:  Repeat for the second injection to get the full dose 

K Repeat all steps starting from step C with the second pre-filled syringe to inject the full dose. The 

second injection should be given on a different site than the one used for the first injection. If you 

wish to use the same injection site, make sure it is not the exact same injection spot.    

 

 

 

+ 

 

 
 

= 1 dose 

 
 

 

 

 


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET